Small Intestinal Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma that arises from the small intestine. Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma. 
Small intestinal adenocarcinomas most frequently harbor alterations in KRAS, TP53, APC, PIK3CA, and SMAD4 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in small intestinal adenocarcinoma .
There are 8 clinical trials for small intestinal adenocarcinoma, of which 7 are open and 1 is completed or closed. Of the trials that contain small intestinal adenocarcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open).
Deficient, MLH1, and MSH2 are the most frequent gene inclusion criteria for small intestinal adenocarcinoma clinical trials .
Paclitaxel, pembrolizumab, and shr1701 are the most common interventions in small intestinal adenocarcinoma clinical trials.
Significant Genes in Small Intestinal Adenocarcinoma
BRAF is altered in 14.68% of small intestinal adenocarcinoma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.